391
Views
3
CrossRef citations to date
0
Altmetric
Review

Emerging molecular target antagonists for the treatment of biliary tract cancer

, , , , &
Pages 63-75 | Received 17 Dec 2017, Accepted 21 Feb 2018, Published online: 28 Feb 2018

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Roberto Filippi, Francesco Leone, Lorenzo Fornaro, Giuseppe Aprile, Andrea Casadei-Gardini, Nicola Silvestris, Andrea Palloni, Maria Antonietta Satolli, Mario Scartozzi, Marco Russano, Stefania Eufemia Lutrino, Pasquale Lombardi, Giorgio Frega, Silvio Ken Garattini, Caterina Vivaldi, Rosella Spadi, Orsi Giulia, Elisabetta Fenocchio, Oronzo Brunetti, Massimo Aglietta & Giovanni Brandi. (2022) Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis. Journal of Chemotherapy 34:2, pages 123-132.
Read now
Wenwei Yang & Yongkun Sun. (2021) Promising Molecular Targets for the Targeted Therapy of Biliary Tract Cancers: An Overview. OncoTargets and Therapy 14, pages 1341-1366.
Read now
Roberto Filippi, Pasquale Lombardi, Virginia Quarà, Elisabetta Fenocchio, Giacomo Aimar, Michela Milanesio, Francesco Leone & Massimo Aglietta. (2019) Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives. Expert Opinion on Pharmacotherapy 20:17, pages 2121-2137.
Read now

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.